이지바이오
Financials
Valuation Metrics
이지바이오's Market Cap is ₩2081B. At end of 2025 it was ₩1922B. Ranked #830 of 2,421 in KR market (top 34%), #379 of 1,640 on KOSDAQ (top 23%), #30 of 84 in Food, Beverage & Tobacco (top 36%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 208.09B KRW | KR#830/2,421 Sec#30/84 |
| Revenue | 525.04B KRW | KR#607/2,421 Sec#38/84 |
| Net Income | 41.93B KRW | KR#475/2,421 Sec#20/84 |
| Total Assets | 385.93B KRW | KR#896/2,421 Sec#46/84 |
| Net Assets | 132.09B KRW | KR#1,214/2,421 Sec#53/84 |
| Employees | 134 | KR#1,411/2,421 Sec#57/84 |
| Value | ||
| P/E | 4.96x | KR#345/2,421 Sec#19/84 |
| P/B | 1.58x | KR#1,803/2,421 Sec#79/84 |
| PEG | 0.01x | KR#86/2,421 Sec#5/84 |
| P/S | 0.40x | KR#759/2,421 Sec#60/84 |
| EV/EBITDA | 6.32x | KR#325/2,421 Sec#17/84 |
| FCF Yield | 13.83% | KR#469/2,421 Sec#36/84 |
| Profitability | ||
| ROE | 31.74% | KR#52/2,421 Sec#1/84 |
| ROA | 10.86% | KR#233/2,421 Sec#3/84 |
| Op. Margin | 10.12% | KR#511/2,421 Sec#10/84 |
| Revenue Growth | 15.45% | KR#671/2,421 Sec#6/84 |
| Earnings Growth | 706.87% | KR#86/2,421 Sec#3/84 |
| Financial Health | ||
| Debt Ratio | 192.18% | KR#2,079/2,421 Sec#67/84 |
| Total Debt | 175.07B KRW | KR#551/2,421 Sec#34/84 |
| FCF | 28.78B KRW | KR#427/2,421 Sec#31/84 |
| Cash | 47.59B KRW | KR#761/2,421 Sec#35/84 |
| Current Ratio | 1.24x | KR#1,473/2,421 Sec#37/84 |
| Net Debt/EBITDA | 2.40x | KR#867/2,421 Sec#25/84 |
| Dividend | ||
| Div. Yield | 3.97% | KR#422/2,421 Sec#22/84 |
| Div. Growth | 25.00% | KR#391/2,421 Sec#17/84 |
| Performance | ||
| 1Y Return | 3.28% | KR#665/2,421 Sec#9/84 |
| 1M Return | 1.13% | KR#1,101/2,421 Sec#31/84 |
| From 52W High | -26.52% | KR#428/2,421 Sec#27/84 |
| 1Y MDD | -28.91% | KR#218/2,421 Sec#22/84 |
| Trading | ||
| Volume | 98,930 shares | KR#787/2,421 Sec#12/84 |
| Trading Value | 616.2M KRW | KR#872/2,421 Sec#20/84 |
| Foreign Own. | 5.55% | KR#786/2,421 Sec#28/84 |
| Per Share | ||
| EPS | 1,267 KRW | KR#625/2,421 Sec#26/84 |
| BPS | 3,993 KRW | KR#1,670/2,421 Sec#66/84 |
Company Info
Established in 2020 through a spin-off from Easy Holdings Co., Ltd., the company was re-listed on KOSDAQ in the same year. It specializes in manufacturing and selling animal pharmaceuticals, compound feed, and functional foods, alongside developing natural antimicrobial substances as antibiotic alternatives. The company differentiates its piglet feed with dedicated production facilities and processing technology, while developing high value-added feed additives based on fermentation engineering. Easy Bio was established in 2020 and is headquartered in Gangnam-gu, Seoul.